US FDA approves manufacturing line for Sanofi's preventive RSV therapy
Reuters · 2d ago
Share
Listen to the news
Sept 16 (Reuters) - Sanofi SASY.PA said on Monday the U.S. Food and Drug Administration has approved a manufacturing line for its and partner AstraZeneca's AZN.L preventive respiratory syncytial virus (RSV) therapy.
(Reporting by Sriparna Roy in Bengaluru; Editing by Shreya Biswas)
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2024 Webull. All Rights Reserved